Case report: Valproic acid and risperidone treatment leading to development of hyperammonemia and mania

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 46, Issue 3, 2007, Pages 356-361

  Carlson, Teri ^a   Reynolds, Charles A ^b   Caplan, Rochelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Adverse treatment effects; Case study; Hyperammonemia; Mania; Risperidone; Valproic acid

Indexed keywords

AMMONIA; ARIPIPRAZOLE; ATOMOXETINE; DEXAMPHETAMINE; ETHOSUXIMIDE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; RISPERIDONE; VALPROIC ACID;

AMMONIA BLOOD LEVEL; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; HOSPITAL ADMISSION; HUMAN; HYPERAMMONEMIA; MAINTENANCE THERAPY; MALE; MANIA; MENTAL HEALTH; PHYSICIAN; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; CHILD; DRUG THERAPY, COMBINATION; HUMANS; HYPERAMMONEMIA; MALE; RISPERIDONE; VALPROIC ACID;

EID: 33847180819     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/chi.0b013e31802ed8b2     Document Type: Article

References (29)

1. Ahn M, Sims K, Frazier J (2005), Risperidone-induced psychosis and depression in a child with a mitochondrial disorder. J Child Adolesc Pyschopharmacol 15:520-525
2. Bertoldo M (2002), Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 41:632
3. Boehles H, Sewell AC, Wenzel D (1996), The effect of carnitine supplementation in valproate-induced hyperammonemia. Acta Paediatr 85:446-449
4. Glauser TA (2004), Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 19(Suppl 1):S25-S38
5. Granneman RG, Schneck DW, Cavanaugh JH, Witt GF (1996), Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry 57:204-206
6. Green WH (2001), Child and Adolescent Clinical Psychopharmacology. Philadelphia: Lippincott Williams & Wilkins
7. Iinuma K, Hayasaka K, Narisawa K, Tada K, Hori K (1988), Hyperaminoacidemia and hyperammonemia in epileptic children treated with valproic acid. Eur J Pediatr 148:267-269
8. Kimmel R, Irwin S, Meyer J (2005), Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Int Clin Psychopharmacol 20:57-58
9. Komatsu M, Kodama S (1986), A study on valproate-induced hyperammonemia. Med J Kobe Univ 47:235-242
10. Kugoh T, Yamamoto M, Hosokawa K (1986), Blood ammonia level during valproic acid therapy. Jpn J Psychiatry Neurol 40:663-668
11. Laub MC (1986a), Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 27:55-59
12. Laub MC (1986b), Hyperammonemia during valproic-acid therapy in pediatric patients. Nervenarzt 57:314-318
13. Laub MC, Paetzke-Brunner I, Jaeger G (1986), Serum carnitine during valproic-acid therapy. Epilepsia 27:559-562
14. Levy RH, Rettenmeier AW, Anderson GD (1990), Effects of polytherapy with phenytoin, carbamazepine, and stiripentol? On formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 48:225-235
15. Mallet L, Babin S, Morais JA (2004), Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. Ann Pharmacother 38:1643-1647
16. Marini AM, Zaret BS, Beckner RR (1988), Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 38:365-371
17. Moreno F, Macey H, Schreiber B (2005), Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry 66:555-558
18. Murphy JV, Marquardt K (1982), Asymptomatic hyperammonemia in patients receiving valproic-acid. Arch Neurol 39:591-592
19. Ohtani Y, Endo F, Matsuda I (1982), Carnitine deficiency and hyperammonemia associated with valproic-acid therapy. J Pediatr 101:782-785
20. Prior TI, Chue TS, Tibbo P, Baker BG (1999), Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 9:301-309
21. Stephen LJ (2003), Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 20:141-152
22. Sund J, Aamo T, Spigset O (2003), Valproic acid and risperidone: a drug interaction [letter]. J Am Acad Child Adolesc Psychiatry 42:1-2
23. Takei M (1983), Hyperammonemia and abnormal nitrogen metabolism caused by anticonvulsants with special reference to epileptic with severe physical and mental disturbances. Psychiatr Neurol Jpn 85:71-82
24. Van Wattum PJ (2001), Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 40:866-867
25. Vargas C, Tannhauser M, Tannhauser S, Barros H (1996), Lithium and valproate combined administration: acute behavioural effects and drug plasma levels. Pharmacol Toxicol 79:87-91
26. Verrotti A, Greco R, Morgese G, Chiarelli F (1999), Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anitconvulsant drugs. Int J Clin Lab Res 29:36-40
27. Vitiello B (2001), Valproic acid and risperidone. J Child Adolesc Psychiatry 40:866-867
28. Wilder BJ (1992), Pharmacokinetics of valproate and carbamazepine. J Clin Psychopharmacol 12:64S-68S
29. Zagryadskaya EI, Ostretsova IB, Nikiforov AA (1999), Inhibitory effect of valproate on weak organic acid uptake in rat renal proximal tubules. Biochem Pharmacol 58:1371-1377